FibroBiologics, Inc. Common Stock (FBLG) S-1 12 Feb 24 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	FibroBiologics, Inc.
Entity Central Index Key	0001958777
Entity Primary SIC Number	2834
Entity Tax Identification Number	86-3329066
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	455 E. Medical Center Blvd.
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77598
City Area Code	(281)
Local Phone Number	671-5150
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	455 E. Medical Center Blvd.
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77598
City Area Code	(281)
Local Phone Number	671-5150
Contact Personnel Name	Pete O’Heeron

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 10,766	$ 2,266	$ 407
Prepaid expenses	27	29	37
Parent company receivable		300
Other current assets	121	30	24
Total current assets	10,914	2,625	468
Property and equipment, net	477
Operating lease right-of-use asset, net	1,908	2,199
Total assets	13,299	4,824	468
Current liabilities
Accounts payable and accrued expenses	820	758	233
Payable to parent	141		225
Operating lease liability, short-term	353	326
Derivative liability		538
Convertible notes payable, net of debt discount		5,451	1,300
Total current liabilities	1,314	7,073	1,758
Operating lease liability, long-term	1,447	1,747
Total liabilities	2,761	8,820	1,758
Stockholders’ equity/(deficit)
Net Parent investment		1,461	1,461
Common Stock, value
Additional paid-in capital	25,177	2,414
Accumulated deficit	(14,640)	(7,872)	(2,751)
Total stockholders’ equity/(deficit)	10,538	(3,996)	(1,290)
Total liabilities and stockholders’ equity/(deficit)	13,299	4,824	468
Series A Preferred Stock [Member]
Stockholders’ equity/(deficit)
Preferred Stock, value
Series B Preferred Stock [Member]
Stockholders’ equity/(deficit)
Preferred Stock, value
Nonvoting Common Stock [Member]
Stockholders’ equity/(deficit)
Common Stock, value	1	1
Series B-1 Preferred Stock [Member]
Stockholders’ equity/(deficit)
Preferred Stock, value
Series C Preferred Stock [Member]
Stockholders’ equity/(deficit)
Preferred Stock, value

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	12,500,000	12,500,000
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0
Series A Preferred Stock [Member]
Preferred stock, shares authorized		8,750,000	8,750,000
Preferred stock, shares issued	8,750,000	8,750,000	8,750,000
Preferred stock, shares outstanding	8,750,000	8,750,000	8,750,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000	2,500,000	2,500,000
Preferred stock, shares issued	4,171,445	381,658	0
Preferred stock, shares outstanding	4,171,445	381,658	0
Common stock, shares issued		381,658
Nonvoting Common Stock [Member]
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares authorized	30,000,000	62,500,000	62,500,000
Common stock, shares issued	28,230,842	28,230,842	0
Common stock, shares outstanding	28,230,842	28,230,842	0
Series B-1 Preferred Stock [Member]
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	74,922	0
Preferred stock, shares outstanding	74,922	0
Series C Preferred Stock [Member]
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Operating expenses:
Research and development	$ 1,595	$ 802	$ 1,147		$ 521
General, administrative and other	4,814	2,361	3,320		1,057
Total operating expenses	6,409	3,163	4,467		1,578
Loss from operations	(6,409)	(3,163)	(4,467)		(1,578)
Other income/(loss)	(213)
Interest expense	(146)	(434)	(654)		(4)
Net loss	(6,768)	(3,597)	$ (5,121)		$ (1,582)
Deemed dividend	(2,573)
Net loss attributable to common stockholders	$ (9,341)	$ (3,597)
Net loss per share, basic	$ (0.33)	$ (0.13)	$ (0.18)	[1]
Net loss per share, diluted	$ (0.33)	$ (0.13)	$ (0.18)	[1]
Weighted-average shares outstanding, basic	28,230,842	28,230,842	28,230,842
Weighted-average shares outstanding, diluted	28,230,842	28,230,842	28,230,842
[1]The Company had no shares of its common stock issued and outstanding during the year ended December 31, 2021.

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity/(Deficit) - USD ($) $ in Thousands	Parent Investment [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2020	$ 1,169						$ (1,169)
Balance, shares at Dec. 31, 2020
Issuance of capital shares upon Company formation
Issuance of capital shares upon Company formation, shares		8,750,000
Capital contributions	292								292
Net loss							(1,582)		(1,582)
Balance at Dec. 31, 2021	1,461						(2,751)		(1,290)
Balance, shares at Dec. 31, 2021		8,750,000
Net loss							(3,597)		(3,597)
Issuance of Non-Voting Common Stock to Parent company members					$ 1	(1)
Issuance of Non-Voting Common Stock to Parent company members, shares					28,179,592
Stock-based compensation expense						233			233
Stock-based compensation expense, shares					51,250
Balance at Sep. 30, 2022	1,461				$ 1	232	(6,348)		(4,654)
Balance, shares at Sep. 30, 2022		8,750,000			28,230,842
Balance at Dec. 31, 2021	1,461						(2,751)		(1,290)
Balance, shares at Dec. 31, 2021		8,750,000
Net loss							(5,121)		(5,121)
Issuance of Non-Voting Common Stock to Parent company members					$ 1	(1)
Issuance of Non-Voting Common Stock to Parent company members, shares					28,179,592
Issuance of Series “B” Preferred shares						2,150			2,150
Issuance of Series "B" Preferred shares, shares			381,658
Stock-based compensation expense						265			265
Stock-based compensation expense, shares					51,250
Balance at Dec. 31, 2022	1,461				$ 1	2,414	(7,872)		(3,996)
Balance, shares at Dec. 31, 2022		8,750,000	381,658		28,230,842
Net loss							(6,768)		(6,768)
Issuance of Non-Voting Common Stock to Parent company members								$ 4,620
Issuance of Non-Voting Common Stock to Parent company members, shares								890,310
Stock-based compensation expense						1,333			1,333
Sale of Series “B” Preferred Stock shares, net of direct costs						14,945			14,945
Sale of Series "B" Preferred Stock shares, net of direct costs, shares			2,570,394
Sale of Series “B-1” Preferred Stock shares, net of direct costs						1,193			1,193
Sale of Series "B-1" Preferred Stock shares, net of direct costs, shares				74,922
Issuance of Series “B” Preferred Stock shares for conversion of Notes and accrued interest						6,404			6,404
Issuance of Series "B" Preferred Stock shares for conversion of Notes and accrued interest, shares			1,219,393
Deemed dividend related to ROFN Agreement derivative liability	(1,461)					(1,112)			(2,573)
Balance at Sep. 30, 2023					$ 1	$ 25,177	$ (14,640)		$ 10,538
Balance, shares at Sep. 30, 2023		8,750,000	4,171,445	74,922	28,230,842

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (6,768)	$ (3,597)	$ (5,121)	$ (1,582)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,333	233	265
Other loss on derivative liability	72
Amortization of convertible notes debt discount	81	254	389
Amortization of operating lease right-of-use asset	291		94
Depreciation expense	16
Changes in operating assets and liabilities:
Change in prepaid expenses	2	(21)	8	(37)
Change in accounts payable and accrued expenses	396	260	525	233
Change in other current assets	(91)	(22)	(6)	(24)
Change in payable to Parent	141
Change in operating lease liability	(273)		(220)
Net cash used in operating activities	(4,800)	(2,893)	(4,066)	(1,410)
Cash flows from investing activities
Purchases of property and equipment	(493)
Net cash used in investing activities	(493)
Cash flows from financing activities
ROFN Agreement payments to Parent	(2,645)
Repayment and proceeds of note receivable from Parent	300	(300)
Proceeds from borrowing from Parent				975
Payment of loan to Parent		(225)	(225)	(750)
Loan to Parent			(360)
Repayment from Parent			60
Proceeds from net Parent investment				292
Proceeds from issuance of convertible notes		4,300	4,300	1,300
Proceeds from issuance of Series B Preferred Stock, net of direct costs	14,945		2,150
Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs	1,193
Net cash provided by financing activities	13,793	3,775	5,925	1,817
Net increase in cash and cash equivalents	8,500	882	1,859	407
Cash and cash equivalents, beginning of period	2,266	407	407
Cash and cash equivalents, end of period	10,766	1,289	2,266	407
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	1
Supplemental disclosure of non-cash investing and financing activities:
Addition to derivative liability for debt issuance discount		538	538
Obtaining operating lease right-of-use asset and liability		2,799	$ 2,293
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest	5,866
Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock	$ 538

Organization, Description of Bu

Organization, Description of Business, and Liquidity	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Description of Business, and Liquidity	1. Organization, Description of Business, and Liquidity Organization and Business FibroBiologics, Inc. (the “Company” or “FibroBiologics”) was originally formed as a limited liability company (“LLC”) under the laws of the State of Texas on April 8, 2021 (“Inception”) and then converted to a Delaware corporation on December 14, 2021. FibroBiologics is an early stage, cell therapy company headquartered in Houston, Texas, developing innovative treatments for chronic diseases using fibroblast cells. The Company’s primary focus is the initiation and progression of preclinical studies and clinical-stage U.S. Food and Drug Administration trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing and other diseases. Prior to Inception, preclinical research and development related to these disease pathways took place under the parent company, SpinalCyte, LLC (the “Parent” or “FibroGenesis”). Going Concern and Management’s Plan The Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure, develops intellectual property and conducts research and development activities. The Company has primarily relied on a combination of angel investors and private debt placements to funds its operations. As of September 30, 2023, the Company had an accumulated deficit of $ 14,640 10,766 4,620 11,518 Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore one reportable segment.	1. Organization, Description of Business, and Liquidity Organization and Business FibroBiologics, Inc. (the “Company”, “FibroBiologics”) was originally formed as an LLC under the laws of the State of Texas on April 8, 2021 (“Inception”) and then converted to a Delaware corporation on December 14, 2021. FibroBiologics is an early stage, cell therapy company headquartered in Houston, Texas, developing innovative treatments for chronic diseases using fibroblast cells. The Company’s primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing and other diseases. Prior to Inception, preclinical research and development related to these disease pathways took place under our parent company, SpinalCyte, LLC (the “Parent”, “FibroGenesis”). Going Concern and Management’s Plan The Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure, develops intellectual property and conducts research and development activities. The Company has primarily relied on a combination of angel investors and private debt placements to funds its operations. As of December 31, 2022, the Company had an accumulated deficit of $ 7,872 2,266 5 10 Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore one reportable segment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying Unaudited Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed balance sheet as of September 30, 2023, condensed statements of operations for the nine months ended September 30, 2023 and 2022, condensed statements of stockholders’ equity/(deficit) for the nine months ended September 30, 2023 and 2022, and condensed statements of cash flows for the nine months ended September 30, 2023 and 2022, are unaudited. These Unaudited Condensed Financial Statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These Unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022. The unaudited condensed financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the nine months ended September 30, 2023 and 2022, the unaudited condensed statements of stockholders’ equity/(deficit) for the nine months ended September 30, 2023 and 2022 and the unaudited condensed statements of cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022, condensed balance sheet included herein was derived from the audited financial statements, but it does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the condensed financial statements related to the nine months ended September 30, 2023 and 2022, are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. During the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, prior to the Company’s formation on April 8, 2021, the financial statements were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021, through the Company’s formation on April 8, 2021, were allocated and included in the Company’s financial statements. The resulting net Parent investment is presented within stockholders’ equity/(deficit) and represents the Parent’s interest in the recorded net assets of the Company. The accompanying Unaudited Condensed Financial Statements do not include any allocations from the Parent other than the net Parent investment included in the beginning stockholders’ equity/(deficit) and have been prepared in accordance with GAAP. In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4 shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the reverse stock split. Use of Estimates The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000 Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from the operations of CROs, CMOs or suppliers would likely have a negative impact on the Company’s business, financial position and results of operations. Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase. Property and Equipment Property and equipment include laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense of $ 16 No Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the nine months ended September 30, 2023 and 2022. Fair Value Measurements Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Unaudited Condensed Financial Statements as prepaid or accrued research and development. Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general, administrative and other expense in the Unaudited Condensed Statements of Operations. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body. Income Taxes On December 14, 2021, the Company converted from a partnership LLC to a C corporation. Subsequent to this date, the Company began accounting for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes	2. Summary of Significant Accounting Policies Basis of Presentation During the initial period during 2021 prior to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, stand-alone financial statements were not historically prepared for FibroBiologics. These Financial Statements have been prepared in connection with the formation and planned public listing of FibroBiologics and, prior to the Company’s formation on April 8, 2021, were derived from the historical accounting records of the Parent. All expenses, assets, and liabilities directly associated with the business activity of the Company as well as certain allocations from the Parent are included in the Financial Statements. Such allocations include the Company’s portion of general and administrative expenses and research and development expenses originally incurred by the Parent prior to the Company’s formation on April 8, 2021, for the disease pathways now pursued by FibroBiologics. The expense allocations were determined by management and derived from the number of patents transferred to the Company through the patent transfer and assignment agreement between FibroBiologics and FibroGenesis. Patents were determined to be the most reasonable basis for allocation because patent development is the main driver of business activity for each entity during the preclinical phase, and they are the strongest proxy for expenses incurred by the Parent on behalf of the Company. Management believes the assumptions underlying the Financial Statements, including the assumptions regarding the allocation of expenses from the Parent, are reasonable. However, amounts recognized by the Company are not necessarily representative of the amounts that would have been reflected in the Financial Statements had the Company operated independently of the Parent as a standalone entity during the periods presented. The accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Net Parent Investment Because the Financial Statements are derived from the historical records of the Parent, the net Parent investment is presented within stockholders’ deficit on the Balance Sheets. As a subsidiary of the Parent, the Company was dependent upon the Parent for all of its working capital and financing requirements prior to entering into the Convertible Note agreements. Financial transactions that relate to FibroBiologics but occurred at the Parent level are accounted for through the net Parent investment account. Accordingly, none of the Parent’s cash, cash equivalents, or debt has been assigned to the Company in the financial statements. Net Parent investment represents the Parent’s interest in the recorded net assets of the Company. Use of Estimates The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Financial Statements; therefore, actual results could differ from those estimates and assumptions. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000 Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs’, CMOs’ or suppliers’ operations would likely have a negative impact on the Company’s business, financial position and results of operations. Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase. Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development. Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body. Income Taxes On December 8, 2021, the Company converted from a partnership LLC to a C-Corp. Subsequent to this date, the Company began accounting for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes, the Company evaluates uncertain tax positions by reviewing against applicable tax law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line in the accompanying Statements of Operations. Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company has early adopted this standard as of January 1, 2021, which is currently reflected in its Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740). The amendments in ASU No. 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was effective for the Company on January 1, 2022, and for interim periods beginning on January 1, 2023. The Company has adopted this standard which is currently reflected in its Financial Statements.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	3. Net Loss Per Share Attributable to Common Stockholders The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Nine Months Ended September 30, (in thousands, except share and per share amounts) 2023 2022 Numerator: Net loss $ (6,768 ) $ (3,597 ) Adjustment to numerator for earnings per share: Deemed dividend (2,573 ) — Net loss attributable to common stockholders $ (9,341 ) $ (3,597 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 28,230,842 28,230,842 Net loss per common share attributable to common stockholders, basic and diluted $ (0.33 ) $ (0.13 ) As further described in Note 6, the Company issued 28,230,842 As further described in Note 10, the Company agreed to pay to FibroGenesis 15% of the gross proceeds from any equity investments in FibroBiologics prior to an IPO, Direct Listing or Sale of the Company to eliminate upon the occurrence of such event the Series A Preferred Stock and its $ 35 1,461 1,112 The Company had $ 5,600 10,000 790,459	3. Net Loss Per Share Attributable to Common Stockholders The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Year Ended December 31, (in thousands, except share and per share amounts) 2022 2021 Numerator: Net loss attributable to common stockholders: $ (5,121 ) $ (1,582 ) Adjustment to numerator for earnings per share: Deemed dividend Net loss attributable to common stockholders $ $ Denominator: Weighted-average number of common shares outstanding, basic and diluted 28,230,842 N/A Net loss per common share attributable to common stockholders, basic and diluted (1) $ (0.18 ) $ N/A (1) The Company had no shares of its common stock issued and outstanding during the year ended December 31, 2021. As further described in Note 6, the Company issued 28,230,842 381,658 The Company had $ 5,600 10,000 801,145

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments As of December 31, 2022, the Company measured its derivative liability related to the conversion option feature in the 2022 Notes, as described in Note 5, at fair value. This derivative liability was classified within Level 3 of the value hierarchy because the liability was based upon a valuation model that used inputs and assumptions including potential outcomes, interest rates, probabilities, and timing. As of September 30, 2023 , The carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, convertible notes payable, and Parent company payable and receivable approximate their fair values due to their short-term maturities. There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the nine months ended September 30, 2023 and 2022.	4. Fair Value of Financial Instruments As of December 31, 2022, the Company measures its derivative liability related to the conversion option feature in the 2022 Notes, as described in Note 5, at fair value. This derivative liability is classified within Level 3 of the value hierarchy because the liability is based upon a valuation model that uses inputs and assumptions including potential outcomes, interest rates, probabilities, and timing. As of December 31, 2021, the Company did not have any financial instruments measured at fair value on a recurring basis. The carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, convertible notes payable, and Parent company payable and receivable approximate their fair values due to their short-term maturities. There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the years ended December 31, 2022 and 2021.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable The Company entered into multiple convertible promissory note agreements in December 2021 (collectively, the “2021 Notes”). Under the 2021 Notes, the Company received $ 1,300 6.0% In the event that the Company issues and sells shares of its capital stock in excess of $ 10,000 Based on the terms of the 2021 Notes, the Company evaluated the conversion option feature in accordance with ASC 815, Derivatives and Hedging At the inception of the 2021 Notes, and at December 31, 2022, the Company determined that an embedded derivative for the conversion feature did not meet the criteria because it met the “indexed to the entity’s own stock” exception and therefore was not required to be bifurcated from the host instrument. The Company issued additional convertible promissory notes between January and April 2022 with a total principal amount of $ 4,300 a) a 15% discount to the offering price of the Company’s common stock in the event of an initial public offering of the Company or b) the quotient of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the 2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion option was recorded at the time the notes were issued and as of December 31, 2022 The interest expense, excluding amortization of the discount recorded on the 2022 Notes, on the 2021 and 2022 Notes for the nine months ended September 30, 2023 and 2022, was $ 65 180 In February 2023, the Company converted the principal and interest on $ 3,700 799,603 1,300 300 353,713 300 66,077 The convertible debt balances consisted of the following at September 30, 2023, and December 31, 2022: Schedule of Convertible Debt (in thousands) September 30, 2023 December 31, 2022 Convertible notes principal $ — $ 5,600 Convertible notes discount — (149 ) Convertible notes payable, net of discount $ — $ 5,451	5. Convertible Notes Payable The Company entered into multiple convertible promissory note agreements in December 2021 (collectively the “2021 Notes”). Under the 2021 Notes, the Company received $ 1,300 6.0% In the event that the Company issues and sells shares of its capital stock in excess of $ 10,000 Based on the terms of the 2021 Notes, the Company evaluated the conversion option feature in accordance with ASC 815 Derivatives and Hedging. It provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. At the inception of the 2021 Notes, and at December 31, 2021 and 2022, the Company determined that an embedded derivative for the conversion feature did not meet the criteria because it met the “indexed to the entity’s own stock” exception and therefore was not required to be bifurcated from the host instrument. The Company issued additional convertible promissory notes between January and April 2022 with a total principal amount of $ 4,300 a) a 15% discount to the offering price of the Company’s common stock in the event of an initial public offering of the Company or b) the quotient of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the 2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion option was recorded at the time the notes were issued and as of December 31, 2022 The interest expense, excluding amortization of the discount recorded on the 2022 Notes, on the 2021 and 2022 Notes for the years ended December 31, 2022 and 2021, was $ 265 4 The convertible debt balances consisted of the following at December 31, 2022 and 2021: Schedule of Convertible Debt (in thousands) 2022 2021 December 31, (in thousands) 2022 2021 Convertible notes principal $ 5,600 $ 1,300 Convertible notes discount (149 ) — Convertible notes payable, net of discount $ 5,451 $ 1,300

Stockholders_ Equity_(Deficit)

Stockholders’ Equity/(Deficit) / Net Parent Investment	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity/(Deficit) / Net Parent Investment	6. Stockholders’ Equity/(Deficit) / Net Parent Investment Authorized Capital - 20,000,000 12,500,000 8,750,000 35,000 62,500,000 28,230,842 28,179,592 51,250 168 In December 2022, the Company amended its Certificate of Incorporation to authorize 2,500,000 381,658 2,150 In January 2023, to reflect the ROFN Agreement with its Parent, as further discussed in Note 10, the Company amended its Certificate of Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series “A” Preferred Stock $ 35,000 In April 2023, the Company amended its Certificate of Incorporation to authorize 10,000,000 5,000,000 5,000,000 During the first nine months of 2023, the Company raised $ 4,620 890,310 10,325 1,680,084 1,193 74,922 8,890 In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to increase to 100,000,000 0.00001 30,000,000 0.00001 2,500 0.00001 13,000 The Series C Preferred Stock is not entitled to dividends, has a liquidation preference of $ 18.00	6. Stockholders’ Deficit / Net Parent Investment Stockholders’ Equity/(Deficit) / Net Parent Investment Authorized Capital - 12,500,000 8,750,000 35,000 62,500,000 28,230,842 28,179,592 51,250 168 None In December 2022, the Company amended its Certificate of Incorporation to authorize 2,500,000 381,658 2,150

Share Subscription Agreement

Share Subscription Agreement	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share Subscription Agreement
Share Subscription Agreement	7. Share Subscription Agreement On November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $ 100,000 Major terms of the agreement include a commitment fee of 2% 700,000 The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather than completing a public listing of its shares.	7. Share Subscription Agreement On November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $ 100,000 Major terms of the agreement include a commitment fee of 2 700,000 The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather than completing a public listing of its shares.

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate Nine Months Ended Nine Months Ended Federal statutory rate (21.0 )% (21.0 )% Permanent items — — True up prior year net operating loss deferred tax asset — (8.7 ) Other changes 0.2 (1.2 ) Change in valuation allowance 20.8 30.9 Total 0.0 % 0.0 % The components of the Company’s net deferred tax assets are as follows: Schedule of Net Deferred Tax Assets (in thousands of dollars) September 30, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryforwards $ 1,862 $ 896 Lease liability 378 435 Capitalized research and development 614 299 Derivative liability — 31 Accrued liabilities 124 81 Stock compensation 99 17 Deferred tax assets 3,077 1,759 Deferred tax liabilities: Lease right-of-use asset (400 ) (462 ) Unamortized debt discount — (31 ) Deferred tax liabilities (400 ) (493 ) Less: valuation allowance (2,677 ) (1,266 ) Net deferred tax assets $ — $ — The Company was initially formed as an LLC and was converted to a Delaware corporation in December 2021. As a result of generating net operating losses during the years ended December 31, 2022 and 2021, the Company had no income tax expense for years ended December 31, 2022 and 2021. As of September 30, 2023, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $ 8,867 Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under Internal Revenue Code (“IRC”) Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the United States must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the United States must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future. The Company has included the impact of this provision, which resulted in a deferred tax asset of approximately $ 614 Management has evaluated the positive and negative evidence bearing upon the realizability of the Company’s net deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at September 30, 2023, and December 31, 2022. The Company will continue to assess the realizability of its deferred tax assets going forward and will adjust the valuation allowance as needed. As of September 30, 2023, and December 31, 2022, the Company had no uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized tax benefits since its inception.	8. Income Taxes A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate 2022 2021 Year Ended December 31, 2022 2021 Federal statutory rate (21.0 )% (21.0 )% Permanent items 0.8 — True up prior year NOL deferred tax asset (6.1 ) — Other changes 1.9 — Change in valuation allowance 24.4 21.0 % Total 0.0 % 0.0 % The components of the Company’s net deferred tax assets are as follows: Schedule of Net Deferred Tax Assets (in thousands of dollars) December 31, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryforwards $ 896 $ — Lease liability 435 Capitalized research and development 299 Derivative liability 31 Accrued liabilities 81 17 Stock compensation 17 Deferred tax assets 1,759 17 Deferred tax liabilities: Lease right-of-use asset (462 ) — Unamortized debt discount (31 ) — Deferred tax liabilities (493 ) — Less: valuation allowance (1,266 ) (17 ) Net deferred tax assets $ — $ — The Company was initially formed as an LLC and was converted to a Delaware corporation in December 2021. As a result of generating net operating losses during the years ended December 31, 2022 and 2021, the Company had no income tax expense for years ended December 31, 2022 and 2021. As of December 31, 2022, the Company had U.S. federal net operating loss (NOL) carryforwards of $ 4,265 Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future. We have included the impact of this provision, which results in a deferred tax asset of approximately $ 299 Management has evaluated the positive and negative evidence bearing upon the realizability of the Company’s net deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2022 and 2021. The Company will continue to assess the realizability of its deferred tax assets going forward and will adjust the valuation allowance as needed. As of December 31, 2022 and 2021, the Company had no uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has not recorded any interest or penalties for unrecognized tax benefits since its inception.

Leases, Commitments and Conting

Leases, Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Leases, Commitments and Contingencies	9. Leases, Commitments and Contingencies The Company has elected in accordance with ASC 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms of 12 months or less, on the Condensed Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a straight-line basis over the lease term based on the most recent contractual terms available. As of December 31, 2021, the Company had entered into two short-term lease agreements for lab and office space. The Company opted on March 30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on May 1, 2022. The extended lease term was 126 months and was accounted for as an operating lease under the ASC 842 guidance for lease accounting. 2,799 2,799 The Company expanded the scope and extended for six months the term for the remaining lease for temporary lab and office space on July 1, 2022, then further expanded the scope on August 1, 2022, and October 7, 2022, which increased the monthly license fee to $ 15 In January 2023, the Company extended this lease for an additional six months and it expired at the end of June 2023. In October 2022, the Company entered into a lease agreement for office space with a term of 62 months, which expires on November 30, 2027. 2,293 7.5% In June 2023, the Company entered into a new lease for temporary lab and office space for its research operations. This lease has a term of 12 months and monthly rent of $ 6 7 Rent expense for the nine months ended September 30, 2023 and 2022, was $ 504 198 2,104 65 As of September 30, 2023, future minimum payments during the remaining period and the next five years are as follows (in thousands): Schedule of Operating Lease Liabilities (in thousands of dollars) 2023 $ 86 2024 477 2025 488 2026 544 2027 509 Thereafter — Total lease payments 2,104 Less: imputed interest (304 ) Total lease liabilities 1,800 Less: current lease liabilities (353 ) Total non-current lease liabilities $ 1,447	9. Leases, Commitments and Contingencies Effective January 1, 2020, the Company adopted ASU 2016-02, Leases (Topic 842) to account for the Company’s leases. The Company elected to apply the short-term lease practical expedient upon adoption. Due to the short-term nature of the leases, the Company elected an accounting policy to not record short-term leases on the Balance Sheets. ASC 842-20-25-2 allows a lessee to elect an accounting policy to not record short-term leases, defined as those with terms of 12 months or less, on the balance sheet. In accordance with GAAP, rent expense for financial statement purposes was recognized on a straight-line basis over the lease term based on the most recent contractual terms available. As of December 31, 2021, the Company had entered into two short-term lease agreements for lab and office space. The Company opted on March 30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on May 1, 2022. The extended lease term was 126 months 2,799 2,799 The Company expanded the scope and extended for six months the term for the remaining lease for temporary lab and office space on July 1, 2022, and then further expanded the scope on August 1, 2022, and October 7, 2022. The monthly license fee increased to $ 15 In October 2022, the Company entered into a lease agreement for office space with a term of 62 months 2,293 7.5 Rent expense under operating leases for the years ended December 31, 2022 and 2021, was $ 392 26 2,484 Maturities of operating lease liabilities as of December 31, 2022, were as follows: Schedule of Operating Lease Liabilities (in thousands of dollars) 2023 $ 466 2024 477 2025 488 2026 544 2027 509 Thereafter — Total lease payments 2,484 Less: imputed interest (411 ) Total lease liabilities 2,073 Less: current lease liabilities (326 ) Total non-current lease liabilities $ 1,747

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions As of December 31, 2021, the Company had an outstanding related party Parent company payable of $ 225 The Company repaid in April 2022 the remaining Parent company payable of $ 225 300 60 300 As described in Note 6, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment, prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions, and d) multiple sclerosis. In January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (“ROFN Agreement”) with its Parent, FibroGenesis. In exchange for FibroGenesis’ consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series A Preferred Stock $ 35,000 15 2,573 323 15 16,418 2,322 no 141	10. Related Party Transactions As of December 31, 2021, the Company had an outstanding related party Parent company payable of $ 225 The Company repaid in April 2022 the remaining Parent company payable of $ 225 300 60 As described in Note 6, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment, prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions, and d) multiple sclerosis.

Share-based Compensation

Share-based Compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	11. Share-based Compensation The Company adopted on August 10, 2022, and the stockholders approved on August 18, 2022, the 2022 Stock Plan (the “Plan”). The Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. In September 2022, the Company issued a total of 101,250 3.28 3,689,750 2.28 2,500 3.28 As of September 30, 2023, and December 31, 2022, there were 8,711,500 12,398,750 Stock-based compensation expense is recognized in the Condensed Statements of Operations as follows: Schedule of Stock Based Compensation Expense (in thousands of dollars) 2023 2022 For the Nine Months Ended September 30, (in thousands of dollars) 2023 2022 Research and development $ 196 $ 100 General, administrative and other 1,137 133 Total stock-based compensation expense $ 1,333 $ 233 Stock-based compensation expense for the nine months ended September 30, 2022, includes $ 168 Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of September 30, 2023, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 5,470 Expected weighted-average period compensation costs to be recognized (years) 3.2 A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2022 101,250 $ 3.28 9.7 — Granted 3,689,750 $ 2.28 10.0 — Exercised — $ — — — Forfeited/Canceled 2,500 $ 3.28 9.0 — Outstanding as of September 30, 2023 3,788,500 $ 2.36 9.4 — Exercisable as of September 30, 2023 56,298 $ 3.28 9.0 — The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Nine Months Ended September 30, 2023 Risk-free interest rate 3.9 % Expected volatility 90 % Expected term (years) 7.0 Expected dividend 0 % During the nine months ended September 30, 2023, the weighted-average grant date fair value of the options granted was $ 1.80	11. Share-based Compensation The Company adopted on August 10, 2022, and the shareholders approved on August 18, 2022, the 2022 Stock Plan (the “Plan”). The Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. The Company issued in 2022 a total of 101,250 3.28 As of December 31, 2022, there were 12,398,750 Stock-based compensation expense is recognized in the Statements of Operations as follows: Schedule of Stock Based Compensation Expense (in thousands of dollars) 2022 2021 For the Years Ended December 31, (in thousands of dollars) 2022 2021 Research and development $ 115 $ — General and administrative 150 — Total stock-based compensation expense $ 265 $ — Stock-based compensation expense for the year ended December 31, 2022, includes $ 168 Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of December 31, 2022, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 169 Expected weighted-average period compensation costs to be recognized (years) 1.7 A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 — — — — Granted 101,250 $ 3.28 10.0 — Exercised — — — — Forfeited/Canceled — — — — Weighted average remaining contractual life (years), forfeited/canceled Outstanding as of December 31, 2022 101,250 $ 3.28 9.7 — Exercisable as of December 31, 2022 19,445 $ 3.28 9.7 — The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Year Ended December 31, 2022 Risk-free interest rate 4.1 % Expected volatility 100 % Expected term (years) 5.4 6.4 Expected dividend 0 % During the year ended December 31, 2022, the weighted-average grant date fair value of the options granted was $ 2.64

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events The Company has evaluated subsequent events through , the date the Unaudited Condensed Financial Statements were available to be issued, and has determined that there were no other events, other than what is disclosed in Notes 2 and 6 and below, which occurred requiring disclosure in or adjustments to the Unaudited Condensed Financial Statements. In November 2023, the Company issued a total of 14,859 10,321	12. Subsequent Events The Company has evaluated subsequent events through April 28, 2023, the date the Financial Statements were available to be issued, and has determined that there were no other events, other than what is disclosed below, which occurred requiring disclosure in or adjustments to the Financial Statements. In January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (“ROFN Agreement”) with its Parent, FibroGenesis. In exchange for FibroGenesis’ consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series “A” Preferred Stock $ 35,000 323 In January 2023, the Company launched a campaign to raise up to $ 5,000 4,990 4,230 867,913 634 114 In January 2023, the Company extended for an additional six months its remaining lease for temporary lab and office space. In February 2023, the Company converted the principal and interest on $ 3,700 799,603 In March 2023, the Company sold an additional 1,680,084 10,325 1,549 In April 2023, the Company amended its Certificate of Incorporation to authorize 10,000,000 5,000,000 5,000,000 1,600 300 353,713 8,388 153 23 In April 2023, FibroGenesis repaid in full the $ 300

Reverse Stock Split

Reverse Stock Split	12 Months Ended
	Dec. 31, 2022
Reverse Stock Split
Reverse Stock Split	13. Reverse Stock Split In October 2023, the Company filed an amended and restated certificate of incorporation with the State of Delaware to immediately effect a 1-for-4 reverse stock split

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Unaudited Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed balance sheet as of September 30, 2023, condensed statements of operations for the nine months ended September 30, 2023 and 2022, condensed statements of stockholders’ equity/(deficit) for the nine months ended September 30, 2023 and 2022, and condensed statements of cash flows for the nine months ended September 30, 2023 and 2022, are unaudited. These Unaudited Condensed Financial Statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These Unaudited Condensed Financial Statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022. The unaudited condensed financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the nine months ended September 30, 2023 and 2022, the unaudited condensed statements of stockholders’ equity/(deficit) for the nine months ended September 30, 2023 and 2022 and the unaudited condensed statements of cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022, condensed balance sheet included herein was derived from the audited financial statements, but it does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the condensed financial statements related to the nine months ended September 30, 2023 and 2022, are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. During the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, prior to the Company’s formation on April 8, 2021, the financial statements were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021, through the Company’s formation on April 8, 2021, were allocated and included in the Company’s financial statements. The resulting net Parent investment is presented within stockholders’ equity/(deficit) and represents the Parent’s interest in the recorded net assets of the Company. The accompanying Unaudited Condensed Financial Statements do not include any allocations from the Parent other than the net Parent investment included in the beginning stockholders’ equity/(deficit) and have been prepared in accordance with GAAP. In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4 shares reverse stock split. All share and per share amounts have been adjusted on a retroactive basis to reflect the effect of the reverse stock split.	Basis of Presentation During the initial period during 2021 prior to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, stand-alone financial statements were not historically prepared for FibroBiologics. These Financial Statements have been prepared in connection with the formation and planned public listing of FibroBiologics and, prior to the Company’s formation on April 8, 2021, were derived from the historical accounting records of the Parent. All expenses, assets, and liabilities directly associated with the business activity of the Company as well as certain allocations from the Parent are included in the Financial Statements. Such allocations include the Company’s portion of general and administrative expenses and research and development expenses originally incurred by the Parent prior to the Company’s formation on April 8, 2021, for the disease pathways now pursued by FibroBiologics. The expense allocations were determined by management and derived from the number of patents transferred to the Company through the patent transfer and assignment agreement between FibroBiologics and FibroGenesis. Patents were determined to be the most reasonable basis for allocation because patent development is the main driver of business activity for each entity during the preclinical phase, and they are the strongest proxy for expenses incurred by the Parent on behalf of the Company. Management believes the assumptions underlying the Financial Statements, including the assumptions regarding the allocation of expenses from the Parent, are reasonable. However, amounts recognized by the Company are not necessarily representative of the amounts that would have been reflected in the Financial Statements had the Company operated independently of the Parent as a standalone entity during the periods presented. The accompanying Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Net Parent Investment		Net Parent Investment Because the Financial Statements are derived from the historical records of the Parent, the net Parent investment is presented within stockholders’ deficit on the Balance Sheets. As a subsidiary of the Parent, the Company was dependent upon the Parent for all of its working capital and financing requirements prior to entering into the Convertible Note agreements. Financial transactions that relate to FibroBiologics but occurred at the Parent level are accounted for through the net Parent investment account. Accordingly, none of the Parent’s cash, cash equivalents, or debt has been assigned to the Company in the financial statements. Net Parent investment represents the Parent’s interest in the recorded net assets of the Company.
Use of Estimates	Use of Estimates The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions.	Use of Estimates The preparation of the Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Financial Statements; therefore, actual results could differ from those estimates and assumptions.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000
Risks and Uncertainties	Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from the operations of CROs, CMOs or suppliers would likely have a negative impact on the Company’s business, financial position and results of operations.	Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs’, CMOs’ or suppliers’ operations would likely have a negative impact on the Company’s business, financial position and results of operations.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase.	Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase.
Fair Value Measurements	Fair Value Measurements Accounting Standards Codification (“ASC”) 820, Fair Value Measurement Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.	Fair Value Measurements Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Unaudited Condensed Financial Statements as prepaid or accrued research and development.	Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Financial Statements as prepaid or accrued research and development.
Patent Costs	Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general, administrative and other expense in the Unaudited Condensed Statements of Operations. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body.	Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body.
Income Taxes	Income Taxes On December 14, 2021, the Company converted from a partnership LLC to a C corporation. Subsequent to this date, the Company began accounting for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes	Income Taxes On December 8, 2021, the Company converted from a partnership LLC to a C-Corp. Subsequent to this date, the Company began accounting for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes, the Company evaluates uncertain tax positions by reviewing against applicable tax law all positions taken by the Company with respect to tax years for which the statute of limitations is still open. ASC 740-10 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The Company recognizes interest and penalties related to the liability for unrecognized tax benefits, if any, as a component of the income tax expense line in the accompanying Statements of Operations.
Recently Adopted Accounting Pronouncements		Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The Company has early adopted this standard as of January 1, 2021, which is currently reflected in its Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740). The amendments in ASU No. 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP or other areas of Topic 740 by clarifying and amending existing guidance. The new standard was effective for the Company on January 1, 2022, and for interim periods beginning on January 1, 2023. The Company has adopted this standard which is currently reflected in its Financial Statements.
Property and Equipment	Property and Equipment Property and equipment include laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five years. Depreciation expense of $ 16 No Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the nine months ended September 30, 2023 and 2022.

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Nine Months Ended September 30, (in thousands, except share and per share amounts) 2023 2022 Numerator: Net loss $ (6,768 ) $ (3,597 ) Adjustment to numerator for earnings per share: Deemed dividend (2,573 ) — Net loss attributable to common stockholders $ (9,341 ) $ (3,597 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 28,230,842 28,230,842 Net loss per common share attributable to common stockholders, basic and diluted $ (0.33 ) $ (0.13 )	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Year Ended December 31, (in thousands, except share and per share amounts) 2022 2021 Numerator: Net loss attributable to common stockholders: $ (5,121 ) $ (1,582 ) Adjustment to numerator for earnings per share: Deemed dividend Net loss attributable to common stockholders $ $ Denominator: Weighted-average number of common shares outstanding, basic and diluted 28,230,842 N/A Net loss per common share attributable to common stockholders, basic and diluted (1) $ (0.18 ) $ N/A (1) The Company had no shares of its common stock issued and outstanding during the year ended December 31, 2021.

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debt	The convertible debt balances consisted of the following at September 30, 2023, and December 31, 2022: Schedule of Convertible Debt (in thousands) September 30, 2023 December 31, 2022 Convertible notes principal $ — $ 5,600 Convertible notes discount — (149 ) Convertible notes payable, net of discount $ — $ 5,451	The convertible debt balances consisted of the following at December 31, 2022 and 2021: Schedule of Convertible Debt (in thousands) 2022 2021 December 31, (in thousands) 2022 2021 Convertible notes principal $ 5,600 $ 1,300 Convertible notes discount (149 ) — Convertible notes payable, net of discount $ 5,451 $ 1,300

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate	A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate Nine Months Ended Nine Months Ended Federal statutory rate (21.0 )% (21.0 )% Permanent items — — True up prior year net operating loss deferred tax asset — (8.7 ) Other changes 0.2 (1.2 ) Change in valuation allowance 20.8 30.9 Total 0.0 % 0.0 %	A reconciliation of the income tax benefit computed using the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Schedule of Effective Income Tax Rate 2022 2021 Year Ended December 31, 2022 2021 Federal statutory rate (21.0 )% (21.0 )% Permanent items 0.8 — True up prior year NOL deferred tax asset (6.1 ) — Other changes 1.9 — Change in valuation allowance 24.4 21.0 % Total 0.0 % 0.0 %
Schedule of Net Deferred Tax Assets	The components of the Company’s net deferred tax assets are as follows: Schedule of Net Deferred Tax Assets (in thousands of dollars) September 30, 2023 December 31, 2022 Deferred tax assets: Net operating loss carryforwards $ 1,862 $ 896 Lease liability 378 435 Capitalized research and development 614 299 Derivative liability — 31 Accrued liabilities 124 81 Stock compensation 99 17 Deferred tax assets 3,077 1,759 Deferred tax liabilities: Lease right-of-use asset (400 ) (462 ) Unamortized debt discount — (31 ) Deferred tax liabilities (400 ) (493 ) Less: valuation allowance (2,677 ) (1,266 ) Net deferred tax assets $ — $ —	The components of the Company’s net deferred tax assets are as follows: Schedule of Net Deferred Tax Assets (in thousands of dollars) December 31, 2022 December 31, 2021 Deferred tax assets: Net operating loss carryforwards $ 896 $ — Lease liability 435 Capitalized research and development 299 Derivative liability 31 Accrued liabilities 81 17 Stock compensation 17 Deferred tax assets 1,759 17 Deferred tax liabilities: Lease right-of-use asset (462 ) — Unamortized debt discount (31 ) — Deferred tax liabilities (493 ) — Less: valuation allowance (1,266 ) (17 ) Net deferred tax assets $ — $ —

Leases, Commitments and Conti_2

Leases, Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Liabilities	As of September 30, 2023, future minimum payments during the remaining period and the next five years are as follows (in thousands): Schedule of Operating Lease Liabilities (in thousands of dollars) 2023 $ 86 2024 477 2025 488 2026 544 2027 509 Thereafter — Total lease payments 2,104 Less: imputed interest (304 ) Total lease liabilities 1,800 Less: current lease liabilities (353 ) Total non-current lease liabilities $ 1,447	Maturities of operating lease liabilities as of December 31, 2022, were as follows: Schedule of Operating Lease Liabilities (in thousands of dollars) 2023 $ 466 2024 477 2025 488 2026 544 2027 509 Thereafter — Total lease payments 2,484 Less: imputed interest (411 ) Total lease liabilities 2,073 Less: current lease liabilities (326 ) Total non-current lease liabilities $ 1,747

Share-based Compensation (Table

Share-based Compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Based Compensation Expense	Stock-based compensation expense is recognized in the Condensed Statements of Operations as follows: Schedule of Stock Based Compensation Expense (in thousands of dollars) 2023 2022 For the Nine Months Ended September 30, (in thousands of dollars) 2023 2022 Research and development $ 196 $ 100 General, administrative and other 1,137 133 Total stock-based compensation expense $ 1,333 $ 233	Stock-based compensation expense is recognized in the Statements of Operations as follows: Schedule of Stock Based Compensation Expense (in thousands of dollars) 2022 2021 For the Years Ended December 31, (in thousands of dollars) 2022 2021 Research and development $ 115 $ — General and administrative 150 — Total stock-based compensation expense $ 265 $ —
Schedule of Unvested Awards and Weighted Average Period	Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of September 30, 2023, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 5,470 Expected weighted-average period compensation costs to be recognized (years) 3.2	Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of December 31, 2022, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 169 Expected weighted-average period compensation costs to be recognized (years) 1.7
Schedule of Stock Option Activity	A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2022 101,250 $ 3.28 9.7 — Granted 3,689,750 $ 2.28 10.0 — Exercised — $ — — — Forfeited/Canceled 2,500 $ 3.28 9.0 — Outstanding as of September 30, 2023 3,788,500 $ 2.36 9.4 — Exercisable as of September 30, 2023 56,298 $ 3.28 9.0 —	A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2021 — — — — Granted 101,250 $ 3.28 10.0 — Exercised — — — — Forfeited/Canceled — — — — Weighted average remaining contractual life (years), forfeited/canceled Outstanding as of December 31, 2022 101,250 $ 3.28 9.7 — Exercisable as of December 31, 2022 19,445 $ 3.28 9.7 —
Schedule of Fair Value of Option Granted Black Scholes	The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Nine Months Ended September 30, 2023 Risk-free interest rate 3.9 % Expected volatility 90 % Expected term (years) 7.0 Expected dividend 0 %	The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Year Ended December 31, 2022 Risk-free interest rate 4.1 % Expected volatility 100 % Expected term (years) 5.4 6.4 Expected dividend 0 %

Organization, Description of _2

Organization, Description of Business, and Liquidity (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accumulated deficit		$ 14,640	$ 7,872	$ 2,751
Cash and cash equivalents		10,766	$ 2,266	$ 407
Proceeds from issuance of crowdfunding offering	$ 5,000	4,620
Proceeds from issuance of private placement offering	$ 10,000	$ 11,518

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Federally insured limit	$ 250,000		$ 250,000
Depreciation	$ 16,000

Schedule of Basic And Diluted N

Schedule of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022		Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ (6,768)	$ (3,597)	$ (5,121)		$ (1,582)
Deemed dividend	2,573
Net loss attributable to common stockholders	$ (9,341)	$ (3,597)
Weighted average number of shares outstanding, basic	28,230,842	28,230,842	28,230,842
Weighted average number of shares outstanding, diluted	28,230,842	28,230,842	28,230,842
Net loss per share, basic	$ (0.33)	$ (0.13)	$ (0.18)	[1]
Net loss per share, diluted	$ (0.33)	$ (0.13)	$ (0.18)	[1]
Net loss	$ (6,768)	$ (3,597)	$ (5,121)		$ (1,582)
Deemed dividend	$ (2,573)
[1]The Company had no shares of its common stock issued and outstanding during the year ended December 31, 2021.

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details Narrative) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jan. 31, 2023	Aug. 18, 2022	Dec. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares issued	0		0
Convertible notes outstanding		$ 5,600	$ 5,600
Capital stock in excess		$ 10,000	$ 10,000
Issued upon conversion of common stock	790,459	790,459	801,145
Nonvoting Common Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares issued	28,230,842		28,230,842		28,230,842	0
Series B Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Common stock, shares issued			381,658
Series A Preferred Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Preferred stock liquidation value	$ 35,000		$ 35,000	$ 35,000	$ 35,000
Series A Preferred Stock [Member] | Maximum [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Preferred stock, redemption amount					1,461
Series A Preferred Stock [Member] | Minimum [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Preferred stock, redemption amount					$ 1,112

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Convertible notes principal		$ 5,600	$ 1,300
Convertible notes discount		(149)
Convertible notes payable, net of discount		$ 5,451	$ 1,300

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($) $ in Thousands			9 Months Ended	12 Months Ended
	Apr. 30, 2023	Feb. 28, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Subsidiary, Sale of Stock [Line Items]
Face value				$ 5,600	$ 1,300
Capital stock in excess				10,000		$ 10,000
Long-term debt, gross				$ 4,300	$ 4,300
Conversion of Stock, Description				a) a 15% discount to the offering price of the Company’s common stock in the event of an initial public offering of the Company or b) the quotient of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the 2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion option was recorded at the time the notes were issued and as of December 31, 2022	a) a 15% discount to the offering price of the Company’s common stock in the event of an initial public offering of the Company or b) the quotient of $200,000 thousand divided by total equity interests prior to the dilution from the offering. The conversion option feature in the 2022 Notes was evaluated in accordance with ASC 815, and a derivative liability for the $538 thousand estimated fair value of the conversion option was recorded at the time the notes were issued and as of December 31, 2022
Accounts payable and accrued expenses			65	$ 265	$ 4	$ 180
2021 Notes [Member]
Subsidiary, Sale of Stock [Line Items]
Face value	$ 1,300
Capital stock in excess				10,000	10,000
2021 Notes [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Converted principal shares	353,713
Two Thousand Twenty Two Notes [Member]
Subsidiary, Sale of Stock [Line Items]
Face value	$ 300	$ 3,700	$ 300
Two Thousand Twenty Two Notes [Member] | Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Converted principal shares		799,603	66,077
IPO [Member] | 2021 Notes [Member]
Subsidiary, Sale of Stock [Line Items]
Face value				$ 1,300	$ 1,300
Debt instrument, interest rate, stated percentage				6%	6%

Stockholders_ Equity_(Deficit_2

Stockholders’ Equity/(Deficit) / Net Parent Investment (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended	9 Months Ended		12 Months Ended
	Apr. 30, 2023	Mar. 31, 2023	Feb. 28, 2023	Jan. 31, 2023	Oct. 31, 2023	Aug. 31, 2022	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 18, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized					100,000,000			20,000,000	12,500,000	12,500,000		12,500,000
Common stock, shares authorized	10,000,000							100,000,000		100,000,000
Common stock, shares issued								0		0
Number of shares issued						28,179,592
Employee benefit plan										51,250
Share based compensation										$ 168,000
Common stock, shares outstanding								0		0
Stock issued during period, value, new issues
Proceeds from issuance of private placement							$ 10,000,000	$ 11,518,000
Warrants issued								8,890
Common stock, par value					$ 0.00001			$ 0.00001		$ 0.00001
Preferred stock, par value								$ 0.00001		$ 0.00001		$ 0.00001
Debt instrument convertible descreption					The Series C Preferred Stock is not entitled to dividends, has a liquidation preference of $18.00 per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder into common stock, and upon closing of an IPO will if transferred automatically convert 1:1 into common stock.
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Liquidation preference				$ 35,000,000
Preferred stock, shares issued				4,230,000
Stock issued during period, value, new issues				$ 4,990,000
Stock issued during period, shares, new issues				867,913
Proceeds from issuance of private placement	$ 153,000
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized										8,750,000		8,750,000
Preferred stock, shares issued								8,750,000		8,750,000		8,750,000
Liquidation preference				$ 35,000,000				$ 35,000,000		$ 35,000,000	$ 35,000,000
Series A Preferred Stock [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Liquidation preference				$ 35,000,000
Nonvoting Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized					30,000,000			30,000,000		62,500,000		62,500,000
Common stock, shares issued								28,230,842		28,230,842	28,230,842	0
Common stock, shares outstanding								28,230,842		28,230,842		0
Stock issued during period, value, new issues						$ 28,179,592
Common stock, par value					$ 0.00001			$ 0.00001		$ 0.00001		$ 0.00001
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized								5,000,000		2,500,000		2,500,000
Preferred stock, shares issued								4,171,445		381,658		0
Common stock, shares authorized	5,000,000
Common stock, shares issued										381,658
Preferred stock, shares issued										$ 2,150,000
Stock issued during period, value, new issues								$ 4,620,000
Stock issued during period, shares, new issues								890,310
Proceeds from issuance of private placement								$ 10,325,000
Principle shares								1,680,084
Stock issued in private placement								1,193
Principle shares								74,922
Series B Preferred Stock [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	10,000,000
Common stock, shares issued	5,000,000
Number of shares issued	353,713
Proceeds from issuance of private placement		$ 10,325,000
Principle shares		1,680,084	799,603
Series B-1 Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized								5,000,000
Preferred stock, shares issued								74,922		0
Common stock, shares authorized	5,000,000
Series B-1 Preferred Stock [Member] | Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	5,000,000
Number of shares issued	8,388
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized					2,500			2,500		2,500
Preferred stock, shares issued								0		0
Preferred stock, par value					$ 0.00001
Sale of stock, price per share					13,000
Preferred stock, liquidation preference per share					$ 18
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized										12,500,000		12,500,000
Preferred Stock [Member] | Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues
Preferred Stock [Member] | Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues
Preferred Stock [Member] | Series B-1 Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized										62,500,000
Common stock, shares issued										28,230,842
Stock issued during period, value, new issues									$ 1,000	$ 1,000
Stock issued during period, shares, new issues									28,179,592	28,179,592

Share Subscription Agreement (D

Share Subscription Agreement (Details Narrative) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	Nov. 12, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issues initial public offering
Description of share subscription agreement		The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather than completing a public listing of its shares.		The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock shares over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee must be paid to the investors if the Company is sold in a private sale transaction rather than completing a public listing of its shares.
Share Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investors sales	$ 100,000
Commitment fee percentage	2%
Shares issues initial public offering	$ 700,000

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory rate	(21.00%)	(21.00%)	(21.00%)	(21.00%)
Permanent items			0.80%
True up prior year net operating loss deferred tax asset		(8.70%)	(6.10%)
Other changes	0.20%	(1.20%)	1.90%
Change in valuation allowance	20.80%	30.90%	24.40%	21%
Total	0%	0%	0%	0%

Schedule of Net Deferred Tax As

Schedule of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 1,862	$ 896
Lease liability	378	435
Capitalized research and development	614	299
Derivative liability		31
Accrued liabilities	124	81	17
Stock compensation	99	17
Deferred tax assets	3,077	1,759	17
Lease right-of-use asset	(400)	(462)
Unamortized debt discount		(31)
Deferred tax liabilities	(400)	(493)
Less: valuation allowance	(2,677)	(1,266)	(17)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 8,867	$ 4,265
Deferred tax assets	$ 614	$ 299

Schedule of Operating Lease Lia

Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2023	$ 86	$ 466
2024	477	477
2025	488	488
2026	544	544
2027	509	509
Thereafter
Total lease payments	2,104	2,484
Less: imputed interest	(304)	(411)
Total lease liabilities	1,800	2,073
Less: current lease liabilities	(353)	(326)
Total non-current lease liabilities	$ 1,447	$ 1,747

Leases, Commitments and Conti_3

Leases, Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands		1 Months Ended				9 Months Ended		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2023	Aug. 31, 2023	Jan. 30, 2023	Oct. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Extended lease term	126 months				62 months				126 months
Operating lease right-of-use asset		$ 1,908				$ 1,908		$ 2,199
Operating lease liability		1,800				1,800		2,073
License fee		15				15		15
Rent expense		7	$ 6			504	$ 198	392	26
Noncancelable lease payments								$ 2,484
Operating lease description	Company had entered into two short-term lease agreements for lab and office space. The Company opted on March 30, 2022, to extend the lease term for one of its leases for lab and office space, with a commencement date for the lease extension on May 1, 2022. The extended lease term was 126 months and was accounted for as an operating lease under the ASC 842 guidance for lease accounting.				Company entered into a lease agreement for office space with a term of 62 months, which expires on November 30, 2027.
Operating lease extend description				Company extended this lease for an additional six months and it expired at the end of June 2023.
Operating Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncancelable lease payments		2,104				2,104
Short-term Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncancelable lease payments		$ 65				$ 65
Short Term Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset	$ 2,799								2,799
Operating lease liability	$ 2,799								$ 2,799
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use asset					$ 2,293
Operating lease liability					$ 2,293
Operating lease discount rate					7.50%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended			9 Months Ended	12 Months Ended
	Jan. 31, 2023	Jan. 30, 2023	Apr. 30, 2022	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 30, 2023	Oct. 31, 2022	Aug. 18, 2022	Jul. 31, 2022
Related Party Transaction [Line Items]
Proceeds related party						$ 975,000
Short term borrowings								$ 60,000		$ 300,000
Parent company receivable					300,000		$ 300,000
Payments for equity investments		$ 323,000		2,322,000
Proceeds from (repayments of) related party debt				16,418,000
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Liquidation preference	$ 35,000,000			35,000,000	$ 35,000,000				$ 35,000,000
Fibro Genesis [Member]
Related Party Transaction [Line Items]
Proceeds related party						$ 225,000
Repayment of related party			$ 225,000
Percentage of gross proceeds from equity investments	15%
Derivative liability				0
Derivative liabilities payable to related parties				$ 141,000
Related Party [Member]
Related Party Transaction [Line Items]
Derivative liability	$ 2,573

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,333	$ 233	$ 265
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	196	100	115
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,137	$ 133	$ 150

Schedule of Unvested Awards and

Schedule of Unvested Awards and Weighted Average Period (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Unrecognized stock-based compensation expense (in thousands)	$ 5,470	$ 169
Expected weighted average period compensation cost	3 years 2 months 12 days	1 year 8 months 12 days

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - $ / shares	1 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	2,500	3,689,750		101,250
Weighted-average exercise price, exercised					$ 2.64
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options, outstanding, beginning balance			101,250
Weighted-average exercise price, outstanding, beginning balance			$ 3.28
Number of options, granted			3,689,750		101,250
Weighted-average exercise price, granted			$ 2.28		$ 3.28
Weighted average remaining contractual life (years), granted			10 years		10 years
Exercise of stock options, shares
Weighted-average exercise price, exercised
Number of options, forfeited/cancelled			2,500
Weighted-average exercise price, forfeited/ cancelled			$ 3.28
Weighted average remaining contractual life (years), forfeited/canceled			9 years
Stock options, outstanding, ending balance			3,788,500		101,250
Weighted-average exercise price, outstanding, ending balance			$ 2.36		$ 3.28
Weighted average remaining contractual life (years), outstanding			9 years 4 months 24 days		9 years 8 months 12 days
Number of options, exercisable			56,298		19,445
Weighted-average exercise price, exercisable			$ 3.28		$ 3.28
Weighted average remaining contractual term, exercisable			9 years		9 years 8 months 12 days

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Granted Black Scholes (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	3.90%	4.10%
Expected volatility	90%	100%
Expected term	7 years
Expected dividend	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term		5 years 4 months 24 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term		6 years 4 months 24 days

Share-based Compensation (Detai

Share-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended		12 Months Ended
	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share based payment award options grants					101,250
shares issued					3.28
Shares available for future issuance			8,711,500		12,398,750
Stock-based compensation expense				$ 168
Weighted-average exercise price					$ 2.64
Weighted-average grant date fair value			$ 1.80		$ 2.64
Number of options granted	2,500	3,689,750		101,250
Strike price per share	$ 3.28	$ 2.28		$ 3.28
Board of Directors and Consultants [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Stock-based compensation expense					$ 168

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 30, 2023

Mar. 31, 2023

Feb. 28, 2023

Jan. 31, 2023

Nov. 30, 2023

Aug. 31, 2022

Mar. 31, 2023

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Aug. 18, 2022

Dec. 31, 2021

Subsequent Event [Line Items]

Proceeds from equity issues

$ 1,193

Issuance of Non-Voting Common Stock to Parent company members

Proceeds from initial public offering

$ 5,000

4,620

Face amount

$ 5,600

$ 1,300

Issuance of private placement

$ 10,000

$ 11,518

Common stock shares authorized

10,000,000

100,000,000

100,000,000

Common stock shares issued

0

0

Number of shares of stock issues

28,179,592

Number of additional shares issued

3.28

Series A Preferred Stock [Member]

Subsequent Event [Line Items]

Liquidation preference

$ 35,000

$ 35,000

$ 35,000

$ 35,000

Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Issuance of Non-Voting Common Stock to Parent company members

$ 4,620

Stock issuance costs

$ 2,150

Shares issued initial public offering

890,310

Principle shares

1,680,084

Issuance of private placement

$ 10,325

Common stock shares authorized

5,000,000

Common stock shares issued

381,658

Series B-1 Preferred Stock [Member]

Subsequent Event [Line Items]

Common stock shares authorized

5,000,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Liquidation preference

35,000

Issuance of Non-Voting Common Stock to Parent company members

4,990

Stock issuance costs

$ 4,230

Shares issued initial public offering

867,913

Proceeds from initial public offering

$ 634

Assets to pay expenses

114

Face amount

$ 3,700

Issuance of private placement

$ 153

Repaid principal

300

Public sale of units

23

Number of additional shares issued

14,859

Subsequent Event [Member] | 2021 [Member]

Subsequent Event [Line Items]

Face amount

1,600

Subsequent Event [Member] | 2022 [Member]

Subsequent Event [Line Items]

Face amount

$ 300

Subsequent Event [Member] | Fibro Genesis [Member]

Subsequent Event [Line Items]

Payment for sale of equity

323

Subsequent Event [Member] | Series A Preferred Stock [Member]

Subsequent Event [Line Items]

Liquidation preference

35,000

Subsequent Event [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Proceeds from equity issues

$ 5,000

Principle shares

1,680,084

799,603

Issuance of private placement

$ 10,325

Repaid principal

$ 1,549

Common stock shares authorized

10,000,000

Common stock shares issued

5,000,000

Number of shares of stock issues

353,713

Subsequent Event [Member] | Series B-1 Preferred Stock [Member]

Subsequent Event [Line Items]

Common stock shares authorized

5,000,000

Number of shares of stock issues

8,388

Subsequent Event [Member] | Series B-1 Preferred Stock [Member] | Investors [Member] | Warrant [Member]

Subsequent Event [Line Items]

Number of warrants issued

10,321

Reverse Stock Split (Details Na

Reverse Stock Split (Details Narrative)	1 Months Ended
	Oct. 31, 2023
Forecast [Member]
Reverse stock split	1-for-4 reverse stock split